The present invention is directed to a pharmaceutical composition comprisedof one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeuticagents which is suitable for the treatment of metabolic disorders includingtype 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance,hyperglycemia, postprandial hyperglycemia, overweight, obesity, includingclass I obesity, class II obesity, class III obesity, visceral obesity and abdominalobesity, and metabolic syndrome.
